Symbiotix Biotherapies, Inc. announces Phase 1 STTR Award from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Boston, MA – September 1, 2014 – Symbiotix Biotherapies, Inc. (“Symbiotix”) today announced that it was awarded a Phase 1 STTR from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Symbiotix’ lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome, and the $397,000 award from NIH enables the completion of important translational studies related to further evaluation of PSA as a novel therapeutic treatment for inflammatory bowel disease (IBD). PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an anti-inflammatory effect through the production of IL-10. “Despite several FDA approved treatments, IBD remains a significant medical and societal burden. Many of the current drugs are either ineffective in large subsets of patients or have severe side effects. New treatment modalities are thus desperately needed,” said Prof. Sarkis Mazmanian, Louis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at California Institute of Technology, and Co-Founder of Symbiotix. “PSA promises to be a safe and effective new oral therapy for the many patients with this disease, as our preclinical work indicates strong efficacy in several animal models with no detectable side effects.” The studies funded through this prestigious award will be conducted by Symbiotix in collaboration with California Institute of Technology.
“At Symbiotix, we are delighted to have received our Company’s second NIH award, and the funding enabled by this award will be instrumental in furthering our program to develop a safe new oral therapy for IBD,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix. “The STTR program is quite competitive, and reciept of this second award brings significant validation to the translational work we are doing to bring to market a first-inclass therapy.”
About Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. was founded on the basis of over a decade of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College, and our Company’s scientific founders are distinguished thought leaders in the microbiome field. At Symbiotix, we are developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. Our lead program represents the first molecule to emerge from the human microbiome, and is a first-in-class oral agent for the treatment of serious immune-mediated diseases. For more information, please visit www.symbiotix-bio.com.